Kepler Capital Remains a Buy on Bayer (0P6S)
Kepler Capital analyst Christian Faitz maintained a Buy rating on Bayer on January 19 and set a price target of €42.00. The company’s shares closed last Monday at €44.40.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Faitz covers the Basic Materials sector, focusing on stocks such as Wacker Chemie AG, BASF SE, and K+S Aktiengesellschaft. According to TipRanks, Faitz has an average return of 6.9% and a 50.91% success rate on recommended stocks.
In addition to Kepler Capital , Bayer also received a Buy from Barclays’s James Gordon CFA in a report issued yesterday. However, on the same day, UBS maintained a Hold rating on Bayer (LSE: 0P6S).
Based on Bayer’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of €9.66 billion and a GAAP net loss of €963 million. In comparison, last year the company earned a revenue of €9.97 billion and had a GAAP net loss of €4.18 billion
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer, Vanderbilt University Medical Center enter five-year collaboration
- Bayer ‘welcomes’ Supreme Court review of Durnell litigation
- U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
- Bayer, Souffle Therapeutics report global licensing agreement for siRNA therapy
